CE-IVD marked kits, commercial expansion of 3500 Dx Series Genetic Analyzer accelerate research to treat human disease

Carlsbad, Calif. – June 12, 2010 – Life Technologies Corporation (NASDAQ: LIFE) is showcasing its latest technologies and demonstrating its commitment to advancing molecular medicine to treat a variety of human clinical diseases, including cancer, at the European Society of Human Genetics Conference (ESHG 2010), which is scheduled from June 12 to 15 in Gothenberg, Sweden.  The company will feature genomic sequencing and analysis products through product introductions and company workshops.

New Kits and Reagent Sets

·         Applied Biosystems® TrueScience™ Aneuploidy Kits for in vitro diagnostic use are CE-IVD marked and feature a powerful multiplex assay that enable scientists to interrogate 22 loci in a single tube, in order to rapidly and accurately identify chromosomal abnormalities that result in disorders, including Down, Patau, Turner and Klinefelter Syndromes.  The kits are optimized to work with Applied Biosystems’ 3500 Series Genetic Analyzers. These kits are currently available in the Czech Republic, Hungary, India, Poland, Romania, Serbia, Slovakia, South Africa and Turkey. IVD registration is pending in Argentina, Australia, Brazil, Canada, Israel, Mexico and New Zealand.  These kits are not available in the U.S. 

·         Applied Biosystems KRAS and BRAF Mutation Analysis Reagents for research-use-only provide thorough coverage for oncology researchers interested in detecting 12 mutations in the KRAS gene and 3 mutations in the BRAF gene. The KRAS and BRAF oncogenes have been implicated in the development of various malignancies, including colon cancer. The reagent sets also leverage the 3500 Series Genetic Analyzers.

Genomic Analysis Instrumentation

  • The 3500 Series Genetic Analyzer builds on Applied Biosystems’ industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease-of-use.  Since the 3500 Dx System was introduced for sale in 7 European countries a year ago, the commercial availability of the platform has been extended into six additional European countries.  This landmark sequencing platform is the first CE system for DNA sequence analysis to be designed and registered for in vitro diagnostic use, now available in 13 European countries, including: Austria, Belgium, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Norway, Spain, Sweden, Switzerland,  and the United Kingdom.  The 3500 Dx Series is the only CE system for DNA sequence analysis to comply with the in vitro Diagnostic Directive on Medical Devices 98/79/EC, helping to advance genetic analysis from the research bench to the clinic.  Outside of Europe, the 3500 Dx Series is now also a registered medical device in Taiwan and Singapore.  The 3500 Dx instrument is not available in the U.S.
  • Several medical institutions studying a number of critical human diseases are using the 3500 Dx System for the analysis of human DNA or RNA.  These institutions include Centre de Recherche Public Santé, Luxembourg (immunology, clinical virology, and oncology); Genetadi Biotech S.L., Spain (gynecology, oncology); Institute for Pathology and Cytodiagnostics, Main-Taunus, Germany (oncology); Institute of Neurology, England (neurology), and Institut Paoli-Calmettes, France (cancer).
  • Applied Biosystems SOLiD™ System was utilized in a study to sequence the genomes of individual of admixed ancestry (link to ESHG release), enabling scientists to greatly increase the resolution of analyses and achieve a very much clearer picture of the ancestry of genome sequences for the African-American and Mexican individuals studied.   The newest additions to the Life Technologies sequencing portfolio, SOLiD 4 and SOLiD PI, use the same highly-accurate ligation-based sequencing technology, have a streamlined workflow, and are engineered to deliver high-quality, sample-to-mapped data in as little as two days.  The accuracy of the SOLiD 4 and SOLiD PI systems help researchers accurately determine rare genetic variants assisting in discovery, and pave the way for more personalized medicine tool development.


Life Technologies Workshops

Partnering with key institutions worldwide, Life Technologies is providing the path to molecular medicine by sponsoring a series of workshops featuring its work with leading researchers from around the globe. These presentations will demonstrate the broad utility, superior accuracy and reliability of Life Technologies’ tools across multiple generations of genetic sequencing and analysis technology – qualities that are important to research from discovery to the clinic. Dr. Tetsuro Noguchi of Institut Paoli-Calmettes will discuss results of research examining molecular testing using the 3500 Dx Series Genetic Analyzers during the Monday, June 14 workshop “Molecular medicine more accessible than ever.

“While conducting our genetic analyses, we found the 3500 Dx Genetic Analyzer to be much easier to configure and, most importantly, includes new features that make it a closed system where there is less room for error.  This is critical in a diagnostic environment,” said Dr. Noguchi.  “The software, management system, consumables and the machine in general are very easy to use with little training, which makes our jobs more efficient and in the long run, more cost-effective in our analyses - a great value for clinical labs and a great savings for hospitals.”

Along with the 3500DX Genetic Analyzer groundbreaking workshop, Alexander Hoischen, PhD, of Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, will discuss using the SOLiD System in the first study to decipher the gene mutation that causes Schinzel-Giedion syndrome in the Next Generation Gene Discovery using the SOLiDTM System workshop on Sunday, June 13.

For more information on Life Technologies at ESHG 2010 visit http://appliedbiosystems.org.uk/eshg/ or stop by booth #B-230.

About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition.  Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better.  Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics.  Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses.  Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products.  For more information on how we are making a difference, please visit us online at www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties.  Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements.  Any statements that are not statements of historical fact are forward-looking statements.  When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements.  Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission.  Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances. 

Booth #B-230

Life Technologies Contact    
Patty Zamora
760.476.7818
Patty.Zamora@lifetech.com 

##End##